Palo Alto, Calif. – October 2nd, 2014 – Glooko Inc., announced today the launch of Glooko MeterSync Blue, strengthening its position as the industry leader in delivering a mobile, software as a service (SaaS) diabetes remote monitoring and population management platform. Now patients can utilize Bluetooth to connect any of more than 30 popular blood glucose meters to the Glooko platform on Android or Apple devices, as an easier alternative to a physical connection with the current Glooko MeterSync cable.

With the addition of the Glooko MeterSync Blue – featuring Bluetooth Smart™ and Glooko’s FDA-cleared technology-the company’s diabetes management platform provides health systems and payer groups the ability to more cost-effectively enroll diabetes patients into remote monitoring programs without the need for patients to switch to costly, wireless-enabled, blood glucose meters developed specifically for telemedicine. Instead, health systems and payer groups can leverage the tens of millions of meters already deployed to patients worldwide.

“Glooko’s ability to sync blood glucose data from several meters and analyze trends has added efficiency within my clinical practice”, said renowned endocrinologist Dr. Zachary Bloomgarden, Clinical Professor at Mt. Sinai Medical Center. “I am looking forward to using Glooko MeterSync Blue, which should make the platform more valuable by ensuring that patients can more seamlessly share their data with me between visits, particularly those at higher risk, including women during pregnancy and poorly controlled patients initiating treatment with insulin. It should also help with patients who are not at high risk but for whom the ability to review home glucose monitoring results will improve adherence to the increasingly complex regimens of modern diabetes management.

“Glooko facilitates remote monitoring with the Glooko Population Tracker, which delivers pattern recognition algorithms and flags for care managers to easily identify patients experiencing potentially harmful amounts of hyperglycemic (high blood glucose) or hypoglycemic (low blood glucose) events in between clinic visits. By allowing patients to wirelessly sync each blood glucose reading after testing, the MeterSync Blue opens the door for Glooko, in collaboration with health systems and payers, to deliver more real-time reminders and recommendations to patients with diabetes.

For example, Glooko and the Joslin Diabetes Center recently deployed ‘Joslin HypoMap™’ that relies on timely blood glucose data to enable providers and patients to better manage hypoglycemia, which is the predominant cause of hospitalizations for patients with diabetes.

About Glooko Inc.
Glooko is an innovative Silicon Valley company that delivers a FDA-cleared, HIPAA-complaint SaaS and mobile platform designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management platform includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes -­ centric analytics and supplies standardized reports, risk flags and insights to health systems and payers via API’s and web-­based tools.

Glooko was founded in 2011 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is Chief Medical Officer. In addition to the founders, investors include Samsung Ven ture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch.

(Boston, Massachusetts and Palo Alto, California) June 11 , 2014 – Joslin Institute for Technology Translation (JITT) at Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care, and Glooko Inc., a mobile, cloud based diabetes management system announced the release of their jointly developed Joslin HypoMap™ powered by Glooko™. Joslin HypoMap, powered by Glooko, is designed to improve health outcomes and reduce costs for use by patients and providers to improve self-management of hypoglycemia (low blood glucose events) as part of their diabetes management program. The Joslin HypoMap will be launched at the American Diabetes Association’s 74th Scientific Sessions, occurring June 13-17, 2014 in San Francisco. Visit us at booth #2149-Joslin Diabetes Center or #2241-Glooko.

Joslin HypoMap powered by Glooko incorporates a data-driven method to identify individuals with diabetes who have hypoglycemia unawareness, a condition that puts patients at higher risk for dangerous hypoglycemia episodes which can result in serious injury, hospitalization and even death. After experiencing a hypoglycemic event, patients are prompted to record symptoms, perceived causes, and self-treatments in the Joslin HypoMap mobile app. The results are then presented in a standardized, informative set of reports that are available to the patient and the designated patient’s care team. Joslin HypoMap powered by Glooko can be an effective self-management tool providing teachable moments with caregivers when patients miss opportunities to identify, record the symptom and treat a hypoglycemic event. The reports can also graphically present identifiable cyclical patterns related to a patient’s lifestyle habits that may contribute to the development of hypoglycemia.

“Patients rarely have an accurate recollection of the factors leading up to a hypoglycemia episode that occurred months before, and the opportunity to identify underlying causes and, therefore, prevent recurrences is lost,” said Howard Wolpert, MD, Director of the Joslin Institute for Technology Translation. “For the first time, clinicians can have substantive discussions about specific hypoglycemic events using key contextual data such as symptoms, causes, and treatments recorded in real-time, and subsequently help patients to improve their diabetes self-management skills and prevent future episodes.”

According to a study by Gurkirpal Singh, MD, Stanford, which was presented at the 2013 ADA Scientific Sessions, hypoglycemia was seen in a s many as 269,000 US hospitalizations for both Type I and Type 2 patients on insulin. This amounted to nearly $13B in charges in 2009. Joslin HypoMap powered by Glooko aims to create awareness in patients around causes and symptoms that precede their severe hypoglycemic events to provide a future knowledge base to avert possible serious consequences.

“Our partnership with Joslin embodies the transformational capabilities of the Joslin Institute for Technology Translation. In engaging patients and their care team in hypoglycemia awareness through the Joslin HypoMap and our mobile platform, we will jointly contribute to needed advances in diabetes self-management tools” said Rick Altinger, CEO, Glooko. “ By combining Joslin HypoMap with Glooko’s meter-agnostic system, we can improve diabetes patient care while also lowering costs to the overall healthcare system.”

In January, Glooko announced its partnership with Joslin Diabetes Center, a global leader in diabetes care, research and education. The stated purpose of the agreement is to use the Joslin clinical expertise and jointly deploy with Glooko an advanced diabetes technology platform that will allow patients to capture glucose and contextual data to allow for improved self-management tools initially involving hypoglycemia awareness.

Glooko’s FDA 510(k) cleared diabetes management system is available to health systems and payers and is designed to be integrated into EHR’s and other health record systems.

Joslin Diabetes Center does not promote or endorse any product. Revenue and fees from the JITT will be invested in digital health to improve patient care.

About Joslin Institute for Technology Translation (JITT)
Joslin Institute for Technology Translation is focused on leveraging the potential of technology with the introduction of clinical solutions and digital health to improve the lives of people with diabetes. JITT pairs Josli n Diabetes Center’s clinical expertise with industry to enhance the development of new and clinically effective technologies and digital health tools; it is uniquely positioned to provide clinical insight for medical devices, technologies and strategies for cost-efficient solutions that improve diabetes care and outcomes.

About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, is committed to advancing diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives a nd offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care. Its mission is to prevent, treat and cure diabetes and the organization’s vision is a world free of diabetes and its complications. For more information, visit http://www.joslin.org .

About Glooko Inc. Glooko is an innovative Silicon Valley company that delivers a mobile and cloud based, diabetes & chronic disease management system designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management system includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes-centric analytics and supplies standardized reports, risk flags and insights to case managers and Providers via API’s and web-based tools.

Glooko was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Ch amath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Vent ures, Judy Estrin, and Dr. Russell Hirsch.

Media Contacts:
Vikram Singh
Glooko
650 -­ 720 -­ 5310
[email protected]

Jeff Bright
Joslin Diabetes Center
617 – 309 -­ 1957
[email protected]

Partners to develop and deploy advanced mobile and web based diabetes management technology and decision 6 support tools for optimal diabetes care

Palo Alto, California & Boston, Massachusetts 7 January 21, 2014 – Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care, and Glooko Inc. have signed an agreement to jointly deploy an advanced diabetes management technology platform that will allow patients to share diabetes management data and in turn use that data through decision 7 making algorithms for optimal and predictive diabetes care. Glooko and Joslin will jointly provide a diabetes management solution globally to health systems, governments and payer groups aiming to improve health outcomes and lower costs.

The agreement allows Joslin Diabetes Center, to create a ‘Virtual Joslin’ service by adding its clinical expertise to Glooko’s innovative diabetes management technology. The Glooko/Joslin service will allow Joslin and other care teams to remotely monitor, coach and guide diabetes patients between their in 7 clinic consultations. The Glooko/Joslin solution will use pattern recognition algorithms to predict when patients are at risk for severe hypoglycemia or other complications and trigger provider interventions before serious complications and costs arise.

“The Glooko/Joslin platform will address a long standing need in diabetes management. The system will engage patients to analyze the factors underlying the fluctuations in their glucose levels and provide prompts to reinforce behavior change and to improve their diabetes self 7 management skills,” said Howard Wolpert , M.D., Director of the Joslin Institute for Technology Translation.

“Glooko’s unique technology gives clinicians the data necessary to close the communication loop with patients in between clinic visits,” said Rick Altinger, Glooko CEO. “Improved data transparency and communication between clinicians and patients can change the way diabetes is managed.”

Glooko offers an FDA 510 (k) cleared diabetes management system focused on making glucose data accessible to both patients and clinicians. The Glooko Diabetes Management System, consisting of the Glooko MeterSync Cable, the engaging Glooko patient mobile application (app) for both iOS and Android, and the Glooko web dashboard, allows glucose data to be downloaded from dozens of meters that are used by tens of millions of people. To download the data, a user must simply connect their glucose meter to their mobile device using the Glooko MeterSync Cable.

From the Glooko app, the glucose data and other key diabetes data like nutrition metrics, exercise, and medication s can be collected and sent to provider 7 accessed web dashboards and EHR’s. This allows healthcare professionals to analyze blood glucose along with other related biometric data, identify at 7 risk patients, and make informed therapeutic decisions. Because the Glooko system works on both iOS and Android mobile operating systems, Glooko currently supports data transfer from 29 glucose meters to dozens of mobile devices.

“We have been watching Glooko closely over the last year as they have been liberating blood glucose data from meters and making it accessible to patients and clinicians for advanced diabetes management,” said John L. Brooks , III, President and CEO of Joslin. “We are excited to work closely with Glooko on the next leap forward to make glucose data actionable. We intend to create a System that will make a significant impact on dramatically improving patient outcomes and lowering costs.”

About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care. Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit www.joslin.org.

About Glooko Inc.
Glooko is an innovative Silicon Valley company with a unique diabetes management solution for patients, health systems, and payer groups. Glooko’s products – the Glooko mobile apps , MeterSync Cable for iOS and Android, and the Glooko Web Dashboard – enable clinicians to remotely access their patients’ blood glucose readings and other related data. The company ’s system allows people with diabetes to download their glucose readings to t heir mobile device. The company was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch.

Media Contacts:
Joslin Contact:
Jeffrey Bright
[email protected]

Glooko Contact:
Rita Sharma
[email protected]

$7 Million Round from Investors including Samsung Venture Investment Corporation to ramp up growth with health providers and payer groups

January 8, 201 4 – Glooko Inc., makers of a FDA-cleared mobile diabetes management system , announced today it has raised $7 million in a Series A-1 round from several new investors including Samsung Venture Investment Company (SVIC ) and Lifeforce Ventures as well as existing investors including The Social + Capital Partnership , Sundeep Madra and Yogen Dalal. Using this investment, Glooko will focus on enabling predictive diabetes care by delivering patient data and decision-making algorithms to health providers and payer groups. Samsung Venture Investment brings in strategic value given Samsung ’s leadership position in the mobile market globally.

“Over the last two years, Glooko has built a diabetes management infrastructure bent on liberating blood glucose data from glucose meters and making it accessible to patients and clinicians,” said Rick Altinger, Glooko’s CEO. “Our next steps are to scale Glooko’s system to global accessibility and to add a layer of analytics and messaging capable of making therapeutic recommendations for diabetes management. The investors who have contributed to this round will help us achieve these goals.” Glooko’s existing investors participated in this financing round with a strong vote of confidence in the company’s vision and direction. “We believe that Glooko can fundamentally disrupt the way diabetes is managed here in the US and other parts of the world,” said Chamath Palihapitiya , Founder & Managing Partner, Social + Capital.

Glooko offers an FDA 510(k) cleared diabetes management system focused on making glucose data accessible to both patients and clinicians. The system includes the Glooko MeterSync Cable and Glooko’s mobile application-when combined, these tools allow for glucose data to be directly transferred from a glucose meter into a mobile device. The mobile apps integrate into the existing Glooko diabetes management web dashboards, which enable healthcare professionals and care management teams to remotely monitor and identify at-risk patients.

Glooko is available on both the iOS and Android operating systems – the company received FDA 510(k) clearance for its Android system and launched it in November . Across both mobile operating systems, Glooko currently supports data transfer between 26 glucose meters and 2 7 mobile devices.

By using Glooko’s population management and analytics tools , health systems and disease management organizations can increase focus on at-risk patients and achieve higher level of adherence to treatment plans among their diabetes population . Scripps Whittier Diabetes Institute is amongst notable health systems that are currently using Glooko’s diabetes management system .

To learn more about Glooko’s enterprise-grade diabetes management system, email [email protected]. To reach Glooko’s Press Team, email [email protected].

About Glooko Inc.
Glooko is an innovative Silicon Valley startup with a unique diabetes management solution for patients, health systems, and payer groups. Glooko’s products – the Glooko mobile app, MeterSync Cable for iOS and Android, and Glooko Web Dashboard – enable clinicians to remotely access their patients’ blood glucose readings and related data. The company does so by allowing people with diabetes to download glucose readings to their smartphone. The company was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin , and Dr. Russell Hirsch.

About Samsung Venture Investment Corporation
Samsung Venture Investment Corporation manages investment and investment-related activities for Samsung affiliate companies. The investment mandate for Samsung Venture Investment Corporation tracks closely to the strategic priorities of Samsung affiliate companies’ core operating divisions, and encompasses investments in semiconductors, displays, telecommunications, and consumer electronics

Android Compatible System Cleared by FDA and App Available in the Google Play Store , Device available on Amazon

PALO ALTO, Calif. – October 29 , 2013 – Glooko, Inc., makers of an innovative mobile solution for diabetes management, today announced it has launched an Android – compatible version of its next generation Glooko Diabetes Management System . The Glooko system for Android, consist ing of the mobile app, MeterSync Cable and web dashboards, is the only FDA – cleared mobile diabetes management system that supports the transfer of blood glucose data direct from dozens of compatible glucose meters into many Android devices .

Glooko’s Android app will integrate into the existing Glooko Diabetes Management web dashboards , which enables healthcare professionals to identify at – risk patients, analyze blood glucose levels for patterns and make informed therapeutic decisions . The new product has been cleared by the FDA ’s 510 (k) process.

” Our diabetes management system aims for universal access for people with diabetes across the globe,” said Ri ck Altinger, Glooko CEO. “By leveraging Android’s market reach, we hope that providers , health systems and payers can efficiently manage their diabetes patients, improve outcomes and lower costs. ” In support of Glooko’s market expansion into health systems , the company recently joined the Samsung Enterprise Alliance Program (SEAP) to leverage Samsung’s extensive global sales and marketing network.

By adding support for the Android mobile operating system, Glooko now provides a diabetes management platform t hat is accessible to tens of m illions of people with diabetes. According to a recent report by c om S core on key trends in t he smartphone industry , Android is ranked as the number one smartphone platform with 52% market share in the US and 65% in Europe . Wi th the addition of Android support , Glooko enable s people with diabetes to easily collect, view and share their blood glucose readings on many Android phones including Samsung, HTC and LG models . For professionals and disease management staffs , the Glooko diabetes management system offers the analytical tools that can enable consistent care across their diabetes patient s along with an improved ability to advise their patients remotely . By using Glooko , health systems aim to create a higher level of adheren ce to treatment plans among their diabetes population.

The Glooko Diabetes Management System for Android runs on devices using the Android operating system , including phones such as the industry leading Samsung Galaxy SIII and S4. Using Glooko’s mobile application, these devices can currently download glucose data from dozens of compatible meters, including but not limite d to Roche’s ACCU – CHEK ® Aviva (Black) , Abbott’s FreeStyle Lite ® , and Lifescan’s OneTouch ® Ultra ® 2 , OneTouch ® UltraLink ® , and a variety of Nipro meters. Glooko expects to add even more devices soon, including additional glucose meters and eventually insulin pumps.

To learn more about Glooko, including a full list of compatible devices, visit https://glooko.com

About Glooko
Glooko™ is an innovative Silicon Valley startup with a unique solution for people with diabetes. Glooko’s products – the Glooko mobile app and MeterSync Cable for iOS and Android – enable people with diabetes to easily collect, view and share the information needed to help them successfully control their blood glucose readings. It has been hailed by users and industry influencers for its ease of use and ability to deliver context t o daily data collected by people with diabetes on both a mobile and web – based platform. The company was founded in 2010 by technologist Yogen Dalal and mobile and web app developer, Sundeep Madra. Endocrinologist Michael S. Greenfield, M.D., is chief medic al officer. The company’s first generation product received FDA 510(k) clearance in December 2012. Many on the Glooko team , including the founders , have a personal connection to diabetes. Glooko is backed by several Silicon Valley innovators including form er Facebook, Apple and Cisco executives. Together they are committed to helping people with diabetes live their lives , while effortlessly managing their diabetes.

PALO ALTO, Calif. – May 2 , 2013 – Glooko, Inc., makers of an innovative mobile solution for diabetes management , has received FDA 510(k) clearance for its next-gen Glooko System including its Glooko iPhone application, MeterSync Cable and web dashboards for both patients and healthcare providers . In addition, the company has announced the hiring of Holly D. McGarraugh as Vice President of Business Development and Rita Sharma as Vice President of Marketing .

The new Glooko System is an improved iPhone diabetes application that delivers analytical capabilities and a set of distinct dashboards for patients and providers. The iPhone application allows patients to log medications and foods, including nutritional data on over 200,000 foods and menus from most major restaurants. Through a web dashboard that translates key blood glucose , carb and medication data into statistics and graphs, providers are better able to manage their patients with diabetes. These new capabilities give providers and their patients a comprehensive way to evaluate blood glucose readings over time so they can create therapy adjustments related to insulin, medication, diet and exercise.

“The Glooko system is the innovation that clinicians have demanded in diabetes care,” said Michael Greenfield, MD, Chief Medical Officer. “Creating a unified diabetes management platform helps clinicians help their patients — more efficiently, more effectively.” The Glooko System now supports 19 of the leading blood glucose monitors , connecting via the MeterSync Cable to extract readings directly from the meter . Providers will also be able to use a kiosk – type system in their practice s to replace proprietary PC – based systems that rely on dozens of meter specific cables and software applications. The new system is expected to come to market in May 2013.

Holly McGarraugh joins the Glooko team as the vice president of business development. McGarraugh brings over 25 years of diabetes industry experience to Glooko. Previously, McGarraugh served as Vice President of Abbott’s in vivo World Wide Business Unit and was Vice President of Professional Relations and Customer Support at TheraSense, makers of the FreeStyle TM blood glucose monitor. McGarraugh was an original start – up management team member at TheraSense, which was subsequently purchased by Abbott for $ 1.2 billion. McGarraugh was an early member of LifeScan, a Johnson and Johnson Company, in a variety of key roles.

Rita Sharma also join s the Glooko team as the vice president of marketing. Sharma comes to Glooko with over 15 years of industry experience in healthcare and diabetes technologies. She spearheaded LifeScan’s strategic shift from measurement to diabetes data management , successfully launching diabetes management products for professionals and people with diabetes globally. Sharma also led Healthcare Market Development for Handspring ( now Palm ) , including a partnership with Roche and Therasense , to bring to market the first generation of smart glucose monitoring products based on the Hand spring mobile platform.

“We are thrilled at the speed and efficiency with which the FDA cleared our latest product through the 510(k) process,” said Rick Altinger, Glooko CEO. “With seasoned diabetes executive s now on the Glooko team, we expect to fundamentally shift the standard of care in diabetes management and achieve the outcomes that providers and patients have been eagerly anticipating.”

Glooko offers a mobile diabetes management solution that transforms the way patients and their healthcare teams interact and manage diabetes. Their first generation product received FDA 510(k) clearance in December 2012 . It allowed patients to seamlessly transfer blood glucose data from all major blood glucose meters to a mobile application. Their next – gen application and cloud platform creates an automatic logbook, including statistics and graphs, which is presented to the healthcare team on a web dashboard or can be integrated into their EHR. The latest solution, at the intersection of population health and patient engagement, aims to disrupt the industry as it has the potential to both improve outcomes and lower costs.

To learn more about Glooko, visit the site at, www.glooko.com

About Glooko
Glooko™ is an innovative Silicon Valley startup with a unique solution for people with diabetes. Glooko’s products – Glooko app for iOS devices and MeterSync Cable – enable people with diabetes to easily collect, view and share the information needed to help them successfully control their blood glucose readings. It has been hailed by users and industry influencers for its ease of use and ability to deliver context to daily data collected by people with diabetes on both a mobile and web – based platform . The company was founded in 2010 by technologist Yogen Dalal and mobile and web app developer, Sundeep Madra. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. Many on the Glooko team including the founders have a personal connection to diabetes. Glooko is backed by several Silicon Valley innovators, including former Facebook, Apple and Cisco executives. Together they are committed to helping people with diabetes live their lives while effortlessly managing their diabetes.

Media Contact
Sidhtara Tep
[email protected]
650 – 521 – 0175

Company boosts senior leadership while launching new charting capabilities for use with its iOS Logbook diabetes management app
PALO ALTO, Calif . – January 17, 2013 – Glooko, Inc., makers of an innovative mobile logbook solution for people with diabetes, today announces the hiring of Rick Altinger as CEO and Dean Lucas as vice president of product development. In addition to growing its team, the company received FDA 510(k) over-the-counter clearance for its products and launches Glooko Logbook Charts to allow people with diabetes to analyze blood glucose readings through visual graphs.

Rick Altinger will serve as Glooko’s first CEO, and brings over 15 years of industry experience in healthcare information technologies. While an executive at Intuit Health, Altinger helped launch the healthcare division’s provider services and drove Intuit’s acquisition of Medfusion in 2010. He also spearheaded Intuit Health’s growth as the leading supplier of patient-provider communication and patient portal services. His technical knowledge and expertise is central to Glooko’s diabetes healthcare platform and its goal of allowing anyone to monitor blood glucose levels regardless of meter or mobile device type. Altinger fills the CEO role held previously on an interim basis by Glooko co-founder and chairman Yogen Dalal.

“Lack of support across multiple meter types and differing data transfer methods have long withheld a truly unified diabetes management solution,” said Glooko CEO Rick Altinger. “Glooko has cracked this code and created a universal diabetes management platform, and I look forward to continued innovation and implementation of Glooko across healthcare as a unifying force in a disjointed ecosystem.”

Dean Lucas also joins the Glooko team as the vice president of product development. Lucas comes to Glooko with over 17 years of experience leading product design and engineering for web and mobile healthcare applications at both Doximity and Epocrates, where he oversaw user interface and product design for mobile healthcare technologies used by over a million healthcare professionals.

Previously only available to users in the European Union, today also marks the debut of Glooko Logbook Charts in the U.S., which gives people using Glooko Logbook a more in-depth analysis and visualization of blood glucose data through easy to read charts that can be shared with healthcare professionals. The charts can be displayed in three formats: chart by time of day, chart by date, and chart by analysis of time of day. These charting capabilities give users and their healthcare team a comprehensive way to compare blood glucose readings over time so they can view how different factors-from diet and exercise to medication and treatments-impact their readings.

Glooko’s MeterSync Cable, Logbook app, and Logbook Charts are available in the United States with 510(k) over-the-counter clearance from the FDA.

“We are thrilled to have worked collaboratively with the FDA to validate our solution as a system capable of being used across the healthcare system,” said Yogen Dalal, Glooko co-founder. “With Rick at the helm and Dean as VP of product development, we look forward to more product innovation that will continue to improve the way diabetes is managed .”

Glooko’s MeterSync Cable and Logbook app provides people with a mobile and accurate platform for syncing blood glucose readings from their blood glucose meters. By simply connecting the MeterSync Cable to one of the 15 compatible blood glucose meters in the U.S. to an iOS device, users can quickly download all of their readings directly into the Logbook app with a single click. This eliminates user error and saves time versus alternatives that depend on manual entry or paper logbooks. The Glooko Logbook app is free and available for download in the iTunes App Store : http://itunes.apple.com/us/app/glooko-logbook-diabetes-take/id471942748?mt=8

The Glooko Logbook Charts spreadsheet is free and available for download from: https://glooko.com/#charts

To purchase the Glooko MeterSync Cable and Glooko IR Adapter and learn more about pricing, visit: https://glooko.com/purchase/logbook/

About Glooko
Glooko™ is an innovative Silicon Valley startup with a unique solution for people with diabetes. Glooko’s products with FDA 510(k) over-the-counter clearance – the MeterSync Cable and Glooko Logbook app for iOS devices – enable people with diabetes to easily collect , view and share the information needed to help them successfully control their blood glucose readings. It has been hailed by users and industry influencers for its ease of use and ability to provide context to daily data collected by people with diabetes. The company was founded in 2010 by technologist Yogen Dalal and mobile and web app developer, Sundeep Madra. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. Many on the Glooko team including the founders have a personal connection to diabetes . Glooko is backed by several Silicon Valley innovators, including former Facebook, Apple and Cisco executives. Together they are committed to helping people with diabetes live their lives while effortlessly managing their diabetes.

For more information: www.glooko.com.

Media Contact:
Olivia Gallion
VSCpr for Glooko
[email protected]
415-677-9125 x 214

Glooko demonstrates the Glooko Logbook app and the Glooko MeterSync Cable at the Annual Canadian Diabetes Association conference

PALO ALTO, Calif. – October 4, 2012 – Glooko, Inc., makers of an innovative mobile logbook solution for people with diabetes , today formally introduces its Glooko ™ Logbook app and Glooko MeterSync Cable for iOS devices in Canada. Glooko will demonstrate its solution at the 15 th Annual CDA/CSEM produced by the Canadian Diabetes Association on October 10-13 in Vancouver , BC. The Glooko Logbook mobile app and Glooko MeterSync Cable make it easier for people with diabetes to collect and view the information they need to monitor the ir blood sugar levels .

According to the Canadian Diabetes Association, diabetes prevalence has doubled since 2000 and is projected to affect almost 11 percent of the country’s population by 2020. This is expected to cost Canada’s health care system 16 billion dollars annually (1) . M any people with Type 2 diabetes can alter the cours e of the disease for the better with adjustments to diet, increased exercise , and careful ly keeping a logbook using products like Glooko’s solution.

Headquartered in Silicon Valley, Glooko has strong Canadian ties that include Sundeep Madra , co-founder of both Glooko and Toronto-based Xtreme Labs , and investor and former Facebook vice president , Chamath Palihapitiya . In addition to Glooko, Palihapitiya has made several investments in the health space with an emphasis on using technology to help prevent illness and lower costs.

“Our investments in companies like Glooko hit squarely at the premise that if you can quantify yourself and better understand your body, you can more proactively manage for prevention in stead of treatment and emergency care,” says Chamath Palihapitiya, founder of The Social+Capital Partnership. “If you can become a better pro-active self manager about your health, it ’s better for your well-being, easier on your wallet, and more efficient for the Canadian health care system overall.

”Like much of the Glooko team, Chamath Palihapitiya also has a personal stake in simplifying life for people with diabetes — several of his family members in Canada have diabetes. He knows firsthand that it requires an immense effort to log a myriad of details to become a better self-manager, including testing blood glucose several times a day, counting carbs in every meal, adjusting medications with each dose, and tracking moods and activity levels.

It has been proven that people can better control their diabetes when they can visualize how their behavior is affecting their blood glucose values. A logbook is an essential tool used to help people gain control by providing valuable insight on how their behaviors affect trends in their blood glucose levels. Additionally, this understanding can lead to more productive conversations with healthcare professionals (2).

“ We’re excited to be here in Vancouver to meet the Canadian diabetes educators and healthcare professionals dedicated to helping people with diabetes take control of their disease,” says Glooko Chairman, Yogen Dalal. “ Without an a ccurate and complete logbook, it’s very difficult for these professionals to better guide treatment and coach the lifestyle changes that can make a difference to their patients’ well-being.”

By simply connecting the Glooko MeterSync Cable to one of 17 popular, Glooko-compatible blood glucose meters, users can quickly and accurately download all of their meter readings directly into the Glooko Logbook iOS app with a single click. This eliminates user error and saves time compared to alternatives that depend on manual entry into mobile apps or paper logbooks, making Glooko one of the easiest and most accurate ways to monitor blood glucose readings.

To provide insight into factors that affect blood glucose levels, users can take notes about carbohydrates consumed , insulin administered and other wellness factors, on the go and in real time. When it ’s time to meet with a physician, diabetes educator or other healthcare professional, Glooko users can easily share their logbook via fax or email.

The Glooko Logbook app is free and available for download in the iTunes App Store : http://itunes.apple.com/us/app/glooko-logbook/id471942748?mt=8

Canadians can purchase the Glooko MeterSync Cable and Glooko IR Adapter online at Well.ca. To learn more about pricing, visit: https://glooko.com/purchase/logbook/

About Glooko
Glooko ™ is an innovative Silicon Valley startup with a unique solution for people with diabetes. In November 2011, Glooko launched the Glooko MeterSync Cable and Glooko Logbook app for iOS devices. The products enable people with diabetes to easily collect and view the information needed to help them successfully con trol their blood glucose readings. It has been hailed by users and industry influencers for its ease of use and ability to provide context to daily data collected by people with diabetes. The company was founded in June 2010 by technologist Yogen Dalal and mobile and web app developer, Sundeep Madra. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. M any on the Glooko team including the founders have a personal connection to diabetes. This is just the beginning as we have plans to sup port more blood glucose meters and smartphones as well as create future products that allow charting and graphing as we pursue FDA clearance.

For more information: www.glooko.com.

Media Contact
Olivia Gallion
VSCpr for Glooko
[email protected]
415-677-9125 x 204

(1 ) Source: Canadian Diabetes Association. Diabetes: Canada at the tipping point — charting a new path. 2011.

(2) Source: Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002). New England Journal of Medicine 346 (39

Which Enables Support for Six New Blood Glucose Meters From Bayer Healthcare, ARKRAY And Walmart’s ReliOn® Brand
Glooko becomes the only product of its kind to support seventeen of the most popular blood glucose meter s for people with diabetes

PALO ALTO, Calif. – September 28, 2012 – Glooko, Inc. , makers of an innovative mobile solution for people to log blood sugar readings, today announces Glooko ™ Logbook 1.5 for iOS devices , with new support for six additional popular blood glucose meters. The company continues in its mission to enable easy monitoring of blood sugar readings u sing a smartphone app that works across the most popular glucose meters available today.

According to the Centers for Disease Control, 18.8 million people in the U.S. have been diagnosed with diabetes, another seven million individuals are believed to be u ndiagnosed , and as many as 79 million are believed to have pre-diabetes. For those living with or at high risk of developing diabetes, lifestyle interventions such as improved diet, exercise and careful monitoring can alter the course of the disease for the better. It has been proven that people can gain better control of their diabetes and become better self-managers when they understand and visualize the effects of their daily activities. Keeping an accurate logbook is an essential tool to achieve this.

“By adding compatibility for meters from ARKRAY and ReliOn ® and additional meters from Bayer, we continue to pursue our goal to provide a meter agnostic logbook solution for anyone with an iOS device, ” says Yogen Dalal, Chairman of Glooko. “It is gratifying when our customers tell us that Glooko Logbook has allowed them to take better control of their diabetes through better glucose and meal monitoring”. Now people with ARKRAY and ReliOn ® meters can take advantage of our simple-to-use Glooko Logbook and Glooko MeterSync Cable. We are also very happy to bring two additional Bayer meters to our compatibility roster, including the brand new CONTOUR ® NEXT EZ that just became available this month.”

All three companies leverage technology and innovation to make a difference in the lives of people with diabetes. On July 24, 2012 , Walmart launched an effort to save diabetes patients in the U.S. up to $60 million annually with Walmart’s exclusive ReliOn ® brand of diabetes products. Bayer’s CONTOUR ® NEXT platform, which includes the CONTOUR ® NEXT EZ blood glucose monitoring system in the United States and the CONTOUR ® XT blood glucose monitoring system in other markets, offers enhanced accuracy and next generation features and is now available in a number of markets. In addition, ARKRAY announced that the GLUCOCARD® Vital and 01 are now listed on the Department of Defense (DoD) Uniform Formulary.

“Managing diabetes is cumbersome and can be overwhelming – it permeates every aspect of an individual’s life and affects people psychologically, physically and financially,” says Sundeep Madra , co-founder of Glooko. “When people with diabetes can use tools that are integrated into their daily lives, they can be encouraged to have more productive conversations with their care circle and modify their lifestyles. Glooko Logbook and the Glooko MeterSync Cable are designed to do just that.”

By simply connecting the Glooko MeterSync Cable to one of the compatible blood glucose meters and an iOS device, users can quickly and accurately download all of their readings directly into the Glooko Logbook app with a single click. This eliminates user error and saves time versus alternatives that depend on manual entry or paper logbooks, which makes Glooko one of the easiest and most accurate ways to monitor blood glucose readings.

To further provide insight into factors that affect blood glucose levels, users can take notes about carbs, insulin and wellness factors , on-the-go in real time. When it i s time to meet with a physician, diabetes educator or other healthcare professional, Glooko users can easily share their logbook summary directly from the app via email or fax.

Glooko is backed by several Silicon Valley innovators, including former Facebook, Apple and Cisco executives. Together they are committed to helping people with diabetes live their lives while effortlessly managing their diabetes.

The Glooko Logbook app is free and available for download in the iTunes App Store : http://itunes.apple.com/us/app/glooko-logbook-diabetes-take/id471942748?mt=8

To purchase the Glooko MeterSync Cable and Glooko IR Adapter and learn more about pricing, visit: https://glooko.com/purchase/logbook/

About ARKRAY
For more than 50 years, ARKRAY has been committed to producing the highest quality products and delivering exceptional support to help improve patient outcomes. ARKRAY manufactures cost-effective diabetes care products and clinical chemistry equipment that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, ins ulin safety syringes, and urine chemistry. ARKRAY prides itself on putting customer service first, with personalized training, industry expertise, and on-going support. http://www.arkrayusa.com

About Walmart Wal-Mart
Stores, Inc. serves customers and members more than 200 million times per week at more than 10,300 retail units under 69 different banners in 27 countries. With fiscal year 2012 sales of approximately $444 billion, Walmart employs more than 2 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy and employment opportunity.  Additional information about Walmart can be found by visiting http://walmartstores.com .

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees ( December 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com .

About Glooko
Glooko ™ is an innovative Silicon Valley startup with a unique solution for people with diabetes. In November 2011, Glooko launched the Glooko MeterSync Cable and Glooko Logbook app for iOS devices. The products enable people with diabetes to easily collect and view the information needed to help them successfully control their blood glucose readings. It has been hailed by users and industry influencers for its ease of use and ability to provide context to daily data collected by people with diabetes. The company was founded in June 2010 by technologist Yogen Dalal and mobile and web app developer, Sundeep Madra. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. Many on the Glooko team including the founders have a personal connection to diabetes. This is just t he beginning as we have plans to support more blood glucose meters and smartphones as well as create future products that allow charting and graphing as we pursue FDA clearance.

For more information: www.glooko.com .

Media Contact:
Olivia Gallion
VSCpr for Glooko
[email protected]
415-677-9125 x 2 1 4

Susan Yarin
Bayer Healthcare
[email protected]
914-366-1738

With Glooko Logbook Charts , people with diabetes can now graph their blood glucose readings to better understand trends.

PALO ALTO, Calif. & LONDON, U.K .–June 27,2012 – Glooko, Inc ., makers of an innovative mobile logbook solution for people with diabetes , today officially launches its Glooko™ Logbook Charts in the European Union and Glooko Logbook History Report in the US, Canada and European Union. The addition of charts take s monitoring blood glucose readings with the Glooko Logbook app a step further, giving people with diabetes a more in – depth analysis of their blood glucose data through graphs oriented by time of day or by date.

According to the World Health Organization , there are over 20 million people diagnosed with diabetes in the European Union . Today’s introduction of Glooko Logbook Charts in the European Union will help people with diabetes monitor their blood glucose readings to gain better control of their diabetes and become better self – managers of the ir condition. Visualizing and understanding the effects of actions and treatments on blood glucose values can ultimately help people gain control , providing them insight on how to modify their lifestyle.  Additionally, this understanding can lead to more productive conversations with healthcare professionals ( 1)

By simply connecting the Glooko MeterSync Cable to one of the 11 compatible blood glucose meters and an iOS device, users can quickly download all of their readings directly into the Glooko Logbook app with a single click. This eliminates user error and saves time versus alternative s that depend on manual entry or paper logbooks, making Glooko one of the easiest and most accurate ways to monitor blood glucose readings on a smartphone. With Glooko Logbook on their phone, users can take notes about carbs, insulin and wellness factors — on the go in real time .

“As an endocrinologist working with patients for 25 years , I know the value of an accurate and thorough logbook and how it’s key to a physician’s ability to better guide their patient’s diabetes treatment,” says Dr. Michael Greenfield, chief medical officer at Glooko. “At Glooko, we are creating a solution that is easy and intuitive with the hope that we can help change behaviors behind managing diabetes . When patients share their Glooko Logbook Charts with their physician, together they can analyze the impact of specific treatments on their blood glucose readings. Those charts are a great catalyst to create an open dialogue about trends and readings out of range. ”

Graphs and statistics are automatically created when users import their Glooko Logbook CSV file into Excel® with Glooko Logbook Charts . The spreadsheet can be downloaded for free here: https://glooko.com/en/product/logbook/.

Glooko Logbook Charts – available in the E.U. only
Glooko Logbook Charts provide s three charting options for users : chart by time of day, chart by date , and chart by analysis of time of day. This gives people a comprehensive way to compare blood glucose readings over time so they can view how different factors — from diet and exercise to medication and treatments — impact their readings.

Some additional benefits of Glooko Logbook Charts include :

Glooko Logbook History Report – available in the U.S., Canada and E.U.
In addition to Glooko Logbook Charts, Glooko also releases its new Glooko Logbook History Report. The feature creates a consolidated record of all of the data in the Glooko Logbook app — including blood glucose readings, meal tags, carbs, insulin and comments — aligned by date and time.

“We’ve entered an era where the intersection between technology and healthcare has come to life,” says Glooko Co – founder and Chairman , Yogen Dalal. “ Glooko bridges blood glucose meters with the smartphones we’re all carrying around with us. Ultimately , we’ re hoping to give people with diabetes more context and meaning behind their blood glucose readings to help them control their condition .

” Glooko is backed by some heavy hitters in Silicon Valley , including former Facebook, Apple, and Cisco executives. Together they are committed to helping people with diabetes live life while effortlessly managing their diabetes.

Currently, Glooko Logbook Charts is only available in the European Union where Glooko products are sold on Amazon.co.uk. Glooko plans to submit Glooko Logbook Charts to the regulatory authorities in the U . S . and Canada as well, so that its customers in the se countries can also enjoy the new features .

The Glooko Logbook app is free and available for download in the iTunes App Store : http://itunes.apple.com/us/app/glooko-logbook-diabetes-take/id471942748?mt=8

To download Glooko Logbook Charts , Glooko Logbook History Report , and learn more about compatible meters, visit: https://glooko.com/en/product/logbook/

To purchase the Glooko MeterSync Cable and Glooko IR Adapter , and learn more about pricing, visit: https://glooko.com/en/purchase/logbook/

About Glooko
Glooko ™ is an innovative Silicon Valley startup with a unique solution for people with diabetes. In November 2011, Glooko launched the Glooko MeterSync Cable and Glooko Logbook app for iOS devices. The products enable people with diabetes to easily collect and view the information needed to help them successfully control their blood glucose readings. It has been hailed by users and industry influencers for its ease – of – use and ability to provide context to daily data collected by people with diabetes. The company was founded in June 2010 by technologist Yogen Dalal, diabetes healthcare executive , Anita Mathew , and mobile and web app developer, Sundeep Madra. Endocrinol ogist, Michael S. Greenfield, M.D. , is chief medical officer. Each founder and many on the Glooko team have a personal connection to diabetes. This is just the beginning of the mission to help people with diabetes live life while effortlessly managing their diabetes.  For more information: www.glooko.com

Media Contact
Olivia Gallion
VSCpr for Glooko
[email protected]
415-677-9125 x 204

(1)Source: Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002). New EnglandJournal of Medicine 346 (393).